Carnosine and bone (Review)
- Hao Yang
- Xiaoli Hou
- Lei Xing
- Faming Tian
Affiliations: Department of Geriatrics, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China, School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China
- Published online on: November 17, 2022 https://doi.org/10.3892/mmr.2022.12899
Copyright: © Yang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Carnosine is a vital endogenous dipeptide that has anti‑inflammatory, antiaging, anti‑crosslinking, antitumor and immune regulatory effects. Numerous cell and animal model studies have proved that carnosine and its compounds promote the proliferation and differentiation of osteoblasts, inhibit osteoclasts and protect chondrocytes. They also regulate the cell cycle of bone progenitor cells and the differentiation of bone marrow mesenchymal stem cells, accelerate fracture healing, delay bone tumor development and ameliorate osteopenia induced by estrogen deficiency or disuse. The correlations between carnosine and activation signal molecules, pluripotent differentiation of bone marrow mesenchymal stem cells and interaction between bone cells are unclear. However, studies have proved that carnosine and its compounds have benefits in preventing and treating specific bone diseases. This makes them potential agents for the treatment of osteoporosis and bone tumors. The present review summarized the existing research on carnosine and its compounds in bone cells and tissue. It focused on the physiological function of carnosine and its compounds in the bone and their effect on bone metabolism‑related diseases, thus providing support for developing new strategies for targeted therapy.